MedTrace Logo

TRIal For Efficacy of Capre on hyperTriglyceridemiA

NCT01455844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 387

Last updated 2014-08-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for 12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high hypertriglyceridemia as compared to a placebo.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

CaPre (TM)

CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.

OTHER

Placebo

2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks

DRUG

CaPre (TM)

CaPre™ 2.0g daily for 12 weeks

Sponsors & Collaborators

  • JSS Medical Research Inc.

    collaborator INDUSTRY

  • Grace Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Jacques Genest, MD, FRCP(C) · Cardiology Division, MUHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-06-30
Completion
2014-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455844 on ClinicalTrials.gov